Locked and loaded: strong TCR signaling primes anti-PD-1 therapy

With continuous T cell receptor (TCR) signaling, T cells can attenuate subsequent antigen responses through adaptive tolerance, thus averting autoimmunity, but potentially also providing refuge to developing cancers. Elliot and coworkers add to our understanding of adaptation via immune checkpoints...

Full description

Saved in:
Bibliographic Details
Published inTrends in immunology Vol. 42; no. 12; pp. 1066 - 1068
Main Authors Correa, Kristina, Dustin, Michael L.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.12.2021
Elsevier Limited
Subjects
Adaptation
Antigens
Autoimmunity
Cancer
Encephalomyelitis
Gene expression
Humans
Immune checkpoint
Immune Tolerance
Immunological tolerance
Immunology
Immunotherapy
Lymphocytes
Lymphocytes T
Melanoma
PD-1 protein
Peptides
Proteins
Receptors, Antigen, T-Cell
Signal Transduction
T cell receptors
T-Lymphocytes
Online AccessGet full text

Cover

More Information
Summary:With continuous T cell receptor (TCR) signaling, T cells can attenuate subsequent antigen responses through adaptive tolerance, thus averting autoimmunity, but potentially also providing refuge to developing cancers. Elliot and coworkers add to our understanding of adaptation via immune checkpoints by exploiting accelerated in vivo adaptive tolerance in the face of strong TCR signaling.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1471-4906
1471-4981
DOI:10.1016/j.it.2021.10.014